Nomenclature of Toso, Fas Apoptosis Inhibitory Molecule 3, and IgM FcR
Hiromi Kubagawa and John E. Coligan coordinated an online meeting to define an appropriate nomenclature for the cell surface glycoprotein presently designated by different names: Toso, Fas apoptosis inhibitory molecule 3 (FAIM3), and IgM FcR (FcmR). FAIM3 and Faim3 are the currently approved symbols for the human and mouse genes, respectively, in the National Center for Biotechnology Information, Ensembl, and other databases. However, recent functional results reported by several groups of investigators strongly support a recommendation for renaming FAIM3/Faim3 as FCMR/Fcmr, a name better reflecting its physiological function as the FcR for IgM. Participants included 12 investigators involved in studying Toso/FAIM3(Faim3)/FmR, representatives from the Human Genome Nomenclature Committee (Ruth Seal) and the Mouse Genome Nomenclature Committee (Monica McAndrews), and an observer from the IgM research field (Michael Carroll). In this article, we provide a brief background of the key research on the Toso/ FAIM3(Faim3)/FcmR proteins, focusing on the ligand specificity and functional activity, followed by a brief summary of discussion about adopting a single name for this molecule and its gene and a resulting recommendation for genome nomenclature committees. The Journal of Immunology, 2015, 194: 4055-4057. In 2010, Shima et al. (5) in Ohno's laboratory showed that a HeLa cell line transiently expressing mouse Toso/Faim3 exhibited weak binding to IgM and that the clustering of Toso/Faim3 with Pigr and Fcamr also was conserved in the mouse genome.
In 2011, Nguyen et al. (6) in Lee's laboratory showed that FasL-induced apoptosis of the human B cell line BJAB and anti-CD3/anti-CD28-activated blood T cells and Jurkat cells correlated inversely with cell surface expression levels of Toso/ FAIM3, which were modulated by Toso miRNA-mediated knockdown and Toso cDNA transduction; no IgM binding was observed with BJAB or Jurkat cells overexpressing Toso/ FAIM3; A38, but not A36, anti-Toso mAb specifically blocked the antiapoptotic function of Toso/FAIM3 in FasLinduced apoptosis assays; and Toso/Faim3-deficient mice were protected from TNF-a-induced liver damage. Vire et al. (7) in Wiestner's laboratory demonstrated that Toso/FcmR was highly expressed on CLL B cells, was internalized upon IgM binding and shuttled to the lysosomes for degradation, and was downmodulated in response to TLR7 and TLR9 activation.
In 2012, Honjo et al. (8) in Kubagawa's laboratory disputed the findings reported by Nguyen et al. (6) and provided data showing that FcmR/Toso bound to IgM and did not affect Fas-mediated apoptosis by an agonistic IgG mAb or native FasL. Nguyen et al. (9) replied that they could not confirm IgM binding by Toso in their hands and cited experimental data from their group and other investigators to support a role for Toso as a general regulator of death receptor signaling via FasL, TNF-a, and TRAIL. Murakami et al. (10) in Coligan's laboratory demonstrated that Toso/FAIM3bearing Jurkat cells and the human NK cell line YTS, as well as Toso on blood NK cells, bound IgM; IgM binding to NK cells correlated with cell surface expression of Toso/FcmR; and overexpression of Toso/FcmR on Jurkat T cells or on blood NK cells expanded in vitro with IL-2 did not rescue them from Fas-mediated apoptosis induced by an agonistic IgG mAb or FasL. They also demonstrated the resistance of such Toso/FcmR-bearing cells to agonistic IgM anti-Fas mAb-induced apoptosis (10) .
Two laboratories (Ohno and Mak) had generated Fcmr/ Toso-deficient mice, and from 2012 to 2015 four groups of investigators independently characterized their phenotypes (11) (12) (13) (14) (15) (16) (17) (18) (19) . Clear differences in the reported phenotypes, in addition to the cellular distribution of FcmR/Toso, were ev-ident but are not discussed in this article because they are not directly related to the topic of this meeting.
In 2013, Ouchida et al. (20) in Wang's laboratory showed that FcmR was not involved in Fas-mediated cell death in thymocytes or in splenic T and B cells before and after activation, because there were no differences in FasL-or agonistic IgG mAb-induced apoptosis between wild-type and Fcmrdeficient mice. Also in 2013, Ding et al. (21) in Heyman's laboratory, in collaboration with Ohno and Wang, showed that mouse FcmR/Faim3, ectopically expressed on BW5147 cells, bound equally well to serum IgM isolated from wildtype and Cm13 mice, although the latter mice produce IgM that cannot activate the classical complement pathway because of a point mutation in position 436 in the m H chain. This confirmed direct binding of IgM to the FcmR, rather than indirect binding through a complement receptor.
In 2014, Kubagawa et al. (22) demonstrated that human FcmR-bearing cells exhibited IgM ligand binding, irrespective of the growth phase in cell culture (constitutive ligand binding activity), whereas mouse FcmR-bearing cells bound to IgM during the early phase, prior to the exponential growth phase (transient ligand-binding activity). The cell surface FcmR levels in FcmR-bearing mouse cells, as determined by receptor-specific mAbs, were not significantly changed during the entire period of culture. Kubagawa et al. (23) showed that preincubation of membrane lysates of FcmR/FAIM3-bearing cells with receptor-specific mAbs completely removed the z60-kDa IgM-reactive protein, and addition of FcmR-blocking mAb (HM7) in apoptosis assays with an agonistic IgM anti-Fas mAb inhibited the interaction of the Fc portion of IgM mAb with FcmR in a dose-dependent manner, thereby promoting apoptosis of FcmR-bearing Jurkat cells.
In 2015, Honjo et al. (24) demonstrated that, although FcmR/FAIM3 binds soluble pentameric IgM with a relatively high avidity of z10 nM (4), FcmR/FAIM3 interacted more efficiently with the Fc portion of IgM Ab when it was bound to the plasma membrane via its Ag-binding Fab regions; this interaction occurred in cis on the same cell surface but not in trans between neighboring cells.
Conclusions
Nolan initially questioned the wisdom of a constant renaming of genes because the literature has often been confused by investigators making premature name changes for proteins to fit their latest published function; several other investigators (Richter, Jacob, Lang, Lee) supported his opinion. Toso was originally renamed by a nomenclature committee to FAIM3. Morse argued against the nomenclature committee's naming based on strong evidence that Toso is an IgM-binding receptor and on its chromosomal localization, which is conserved in both species, adjacent to two other IgM-binding receptors (pIgR and Fca/mR). He proposed naming the gene FCMR for human and Fcmr for mouse. Wiestner and Ohno supported the FcmR nomenclature. Lee also raised a concern that studies describing the IgM-binding activity mainly dealt with human Toso/FAIM3/FcmR. Kubagawa responded to this concern by providing data showing that mouse FcmR/ Faim3 indeed binds IgM, but it does so only transiently, unlike the constitutive IgM binding by the human receptor. A recent article by Ding et al. (21) supporting this observation was cited. In the end, Nolan agreed that he would be amenable to a name change recommended by the consensus. Although Wang agreed to rename Toso/Faim3 as FcmR, he raised the possibility of a survival-enhancing function of FcmR in murine B cells. In conclusion, based on all of the correspondence during the meeting, we highly recommend renaming the genes FAIM3 (for humans) and Faim3 (for mice) as FCMR and Fcmr, respectively.
